EcoDrugPlus

Ribosomal Protein L21

Ensembl ID : ENSCABG00000001202
Gene Symbol: RPL21
1 Cross references
756 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L23

Ensembl ID : ENSCABG00000000213
Gene Symbol: RPL23
1 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L24

Ensembl ID : ENSCABG00000003959
Gene Symbol: RPL24
1 Cross references
319 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L26

Ensembl ID : ENSCABG00000014147
Gene Symbol: RPL26
1 Cross references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L29

Ensembl ID : ENSCABG00000014209
Gene Symbol: RPL29
1 Cross references
413 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L3

Ensembl ID : ENSCABG00000015241
Gene Symbol: RPL3
1 Cross references
268 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L34

Ensembl ID : ENSCABG00000003992
Gene Symbol: RPL34
1 Cross references
356 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L35

Ensembl ID : ENSCABG00000000871
Gene Symbol: RPL35
1 Cross references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L38

Ensembl ID : ENSCABG00000011815
Gene Symbol: RPL38
1 Cross references
240 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L39

Ensembl ID : ENSCABG00000017482
Gene Symbol: RPL39
1 Cross references
180 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L4

Ensembl ID : ENSCABG00000016134
Gene Symbol: RPL4
1 Cross references
336 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L5

Ensembl ID : ENSCABG00000006064
Gene Symbol: RPL5
1 Cross references
479 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).